Welcome to our dedicated page for Hcw Biologics SEC filings (Ticker: HCWB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The HCW Biologics Inc. (NASDAQ: HCWB) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-assisted summaries to help interpret complex documents. As a clinical-stage biopharmaceutical company developing fusion protein immunotherapies for inflammation-driven and age-related diseases, HCW Biologics uses its SEC filings to report on clinical progress, licensing transactions, financing activities, and Nasdaq listing status.
Investors can review Form 10-K and Form 10-Q filings for detailed discussions of the company’s TOBI and TRBC platforms, pipeline candidates such as HCW9302, HCW11-040, HCW11-018b, and HCW11-006, risk factors, and management’s analysis of operations and liquidity. Form 8-K current reports highlight material events, including warrant inducement agreements that generated gross proceeds from the exercise of existing warrants, securities purchase agreements, licensing and co-development arrangements with partners like Beijing Trimmune Biotech Co., Ltd., and notices from Nasdaq regarding compliance with Listing Rule 5550(b)(1) for continued listing.
Users can also track NT 10-Q notifications of late filings, which explain delays in quarterly reports, and amended 8-K filings that correct or update prior disclosures. Where applicable, Form 4 insider transaction reports can be reviewed to see equity dealings by officers, directors, or significant shareholders, providing additional context on insider activity.
Stock Titan’s AI tools summarize lengthy filings, highlight key terms such as going concern discussions, equity financing plans, and license fee structures, and surface references to clinical milestones like the initiation and design of the Phase 1 trial for HCW9302. Real-time updates from EDGAR ensure that new HCWB filings appear promptly, while AI-generated overviews help users quickly understand how each document relates to the company’s pipeline, partnerships, capital structure, and Nasdaq listing obligations.
HCW Biologics Inc. reported that Nasdaq has notified the company it is not in compliance with Nasdaq Listing Rule 5550(b)(1), known as the equity requirement for continued listing on the Nasdaq Capital Market, based on its status as of June 30, 2025. Nasdaq has informed the company that its securities are scheduled to be suspended from trading on August 28, 2025 unless it requests a hearing by August 26, 2025. The company plans to timely request a hearing before a Nasdaq Hearings Panel, which would pause any trading suspension while the hearing process is completed. HCW Biologics notes there is no assurance the Panel will grant continued listing or that it will be able to regain and demonstrate compliance within any period set by the Panel.
HCW Biologics reported a busy quarter with financing, licensing and construction developments that materially affect liquidity and operations. The company executed a one-for-forty reverse stock split effective April 11, 2025 and completed multiple financings: a registered direct/private placement that closed November 20, 2024, a follow-on public offering that closed May 15, 2025 raising gross proceeds of $5.0 million, bridge loans of $150,000 and $270,000 (the latter converted to equity), and other equity-related transactions valued at $15.2 million fair value of securities issued. HCW amended a license with WY Biotech that includes a $7.0 million upfront fee now expected by September 30, 2025, though revenue was not recognized because collectability was not probable. The company faces construction-related mechanics liens and litigation (BE&K, Fisk and related motions), reflected short-term debt classification due to lender acceleration rights, and recorded a $1.3 million fraud loss. A troubled debt restructuring converted $6.6 million of secured notes into equity, producing a non-cash gain recorded to additional paid-in capital.
HCW Biologics Inc. filed an amended Form 8-K/A to correct a clerical error about the timing of a press release. The amendment explains that the press release announcing financial results was issued on August 18, 2025 instead of August 14, 2025, as originally indicated.
The company states that no other disclosures from the original report are being updated and that the amendment should be read together with the original filing and later SEC filings. The press release for the quarter ended June 30, 2025 is furnished as Exhibit 99.1, not deemed “filed” under the Exchange Act.
HCW Biologics Inc. submitted a Form NT for its periodic report covering the period ended June 30, 2025, notifying the SEC that its Form 10-Q will be filed within the five-day grace period under Rule 12b-25. The notice identifies a prior quarter arbitration as the driver of materially higher legal costs in Q2 2024: $10.4 million of legal fees in Q2 2024 versus $142,452 in the same period of 2025, and states the arbitration was settled on July 13, 2024. The company lists Rebecca Byam, Chief Financial Officer, as the contact for the notification. The registrant indicates all other periodic reports required over the prior 12 months have been filed.
HCW Biologics Inc. filed a current report to furnish a press release announcing its financial results for the quarter ended June 30, 2025. The company issued this press release on August 14, 2025, and attached it as Exhibit 99.1. The information in this report, including the exhibit, is designated as furnished rather than filed under securities law, which limits certain legal liabilities and incorporation into other registration statements.
HCW Biologics (Nasdaq: HCWB) filed an 8-K announcing it has regained full compliance with Nasdaq Capital Market rules, including Listing Rule 5550(b)(1) on minimum shareholders’ equity. Earlier, on May 13, 2025, Nasdaq confirmed compliance with the bid-price, public-float and market-value requirements.
All prior delisting proceedings are now closed. However, HCWB will remain under a “Panel Monitor” until June 23, 2026. Any breach of the Equity Rule during this one-year period would trigger an immediate hearing without the usual compliance-plan option. No financial results were disclosed.
HCW Biologics held its 2025 Annual Meeting of Stockholders on June 17, 2025, marked by technical difficulties with their service provider Broadridge Financial Solutions that affected virtual attendance. Despite these issues, the meeting achieved a quorum through in-person and proxy attendance.
Key developments include:
- Director Resignation: Gary M. Winer resigned from the Board of Directors immediately after the meeting. His resignation was not due to any disagreements with company operations or policies
- Director Election Results: Scott T. Garrett was successfully elected as Class I director with 534,541 votes in favor, while Gary M. Winer received significantly less support with only 133,365 votes in favor
- Auditor Appointment: Stockholders ratified Crowe LLP as the independent registered public accounting firm with overwhelming support (693,874 votes in favor)
To address the technical issues, the company will provide stockholders access to meeting replay until June 2026 and accept questions through July 31, 2025, via email at info@hcwbiologics.com.